The Role of Mismatch Repair Deficiency in the Treatment, Diagnosis, and Pathophysiology of Endometrial Cancer
DOI:
https://doi.org/10.58445/rars.298Keywords:
mismatch repair deficiency, endometrial cancer, immunotherapy, dostarlimab, pembrolizumabAbstract
Endometrial cancer impacts thousands of women worldwide and has many risk factors. Risk factors include obesity, diabetes, infertility, history of endometrial hyperplasia, menstruating before the age of twelve, having menopause later, or receiving estrogen replacement therapy. Mismatch repair deficiency is found in about 30% of endometrial cancers and worsens the prognosis as well as increases the recurrence rate of endometrial cancer. Currently, most common treatments for cancer are chemotherapy and surgery. To combat endometrial cancer with mismatch repair deficiency, immunotherapy has gained traction. Immunotherapy has considerably fewer side effects than the more invasive treatments currently being used. Specifically, drugs, like dostarlimab and pembrolizumab, are used to trigger the immune system to fight the cancer cells. This review article focuses on the effect mismatch repair deficiency has on the progression of endometrial cancer as well as the efficacy of immunotherapy drugs on mismatch repair deficient endometrial cancer.
References
“Key Statistics for Endometrial Cancer.” Information and Resources about for Cancer: Breast, Colon, Lung, Prostate, Skin, www.cancer.org/cancer/endometrial-cancer/about/key-statistics.html. Accessed 18 May 2023.
Loukovaara, M., Pasanen, A., & Bützow, R. (2021). Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Molecularly Classified Endometrial Carcinoma. Cancers, 13(13), 3124. https://doi.org/10.3390/cancers13133124
Oaknin, A., Tinker, A. V., Gilbert, L., Samouëlian, V., Mathews, C., Brown, J., Barretina-Ginesta, M. P., Moreno, V., Gravina, A., Abdeddaim, C., Banerjee, S., Guo, W., Danaee, H., Im, E., & Sabatier, R. (2020). Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. JAMA oncology, 6(11), 1766–1772. https://doi.org/10.1001/jamaoncol.2020.4515
O'Malley, D. M., Bariani, G. M., Cassier, P. A., Marabelle, A., Hansen, A. R., De Jesus Acosta, A., Miller, W. H., Jr, Safra, T., Italiano, A., Mileshkin, L., Amonkar, M., Yao, L., Jin, F., Norwood, K., & Maio, M. (2022). Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study. Gynecologic oncology, 166(2), 245–253. https://doi.org/10.1016/j.ygyno.2022.06.005
Kim, S. R., Pina, A., Albert, A., McAlpine, J. N., Wolber, R., Gilks, B., Carey, M. S., & Kwon, J. S. (2020). Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 30(6), 783–788. https://doi.org/10.1136/ijgc-2019-000910
Dong, D., Lei, H., Liu, D., Bai, H., Yang, Y., Tang, B., Li, K., Liu, J., Xu, G., & Xiao, X. (2021). POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy. Frontiers in oncology, 11, 640018. https://doi.org/10.3389/fonc.2021.640018
McMeekin, D. S., Tritchler, D. L., Cohn, D. E., Mutch, D. G., Lankes, H. A., Geller, M. A., Powell, M. A., Backes, F. J., Landrum, L. M., Zaino, R., Broaddus, R. D., Ramirez, N., Gao, F., Ali, S., Darcy, K. M., Pearl, M. L., DiSilvestro, P. A., Lele, S. B., & Goodfellow, P. J. (2016). Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(25), 3062–3068. https://doi.org/10.1200/JCO.2016.67.8722
Singh, V., Sheikh, A., Abourehab, M. A. S., & Kesharwani, P. (2022). Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment. Biosensors, 12(8), 617. https://doi.org/10.3390/bios12080617
Stelloo, E., Jansen, A. M. L., Osse, E. M., Nout, R. A., Creutzberg, C. L., Ruano, D., Church, D. N., Morreau, H., Smit, V. T. H. B. M., van Wezel, T., & Bosse, T. (2017). Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 28(1), 96–102. https://doi.org/10.1093/annonc/mdw542
Downloads
Posted
Categories
License
Copyright (c) 2023 Tisya Yadav
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.